Plain-English translation of NCT03982160 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This research study is testing whether , a natural amino acid, can help reduce sympathetic nerve overactivity—a condition where your nervous system becomes overactive—and lower blood pressure in people with chronic kidney disease. Researchers believe that kidney disease causes a buildup of a substance called ADMA that interferes with your body's ability to produce nitric oxide, a chemical that helps relax blood vessels. The study will measure whether infusing can restore this natural process and calm your overactive nerves.
People with chronic kidney disease often experience high blood pressure and excessive nervous system activity that standard treatments don't always fully control. This medication may offer a new way to address the root cause of these problems by restoring a natural chemical process in your body.
You will visit the laboratory once, having fasted overnight and avoided caffeine, alcohol, and exercise for 12–24 hours beforehand. Researchers will place an IV catheter in your arm and attach several monitoring devices to measure your heart rhythm, blood pressure, and nerve activity. You will then receive either the infusion or a placebo saline infusion over 30 minutes while your body's responses are continuously recorded. The entire visit will take several hours, and you'll be monitored closely throughout.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States